Literature DB >> 19129505

PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids.

K Tan1, R Roda, L Ostrow, J McArthur, A Nath.   

Abstract

BACKGROUND: Progressive multifocal leukoencephalopathy (PML) is an opportunistic infection that develops in immunosuppressed patients with HIV infection. Paradoxically, some of these patients may develop PML during combined antiretroviral therapy in the setting of immune reconstitution. We describe the types of PML in relation to immune reconstitution inflammatory syndrome (IRIS) and the effects of steroid use in these patients.
METHODS: We performed a retrospective review of the literature (1998 to 2007) and of all HIV-infected patients diagnosed with PML-IRIS at Johns Hopkins Hospital (2004 to 2007). We recorded information on clinical features, microbiologic and virological analysis, neuroimaging, pathology, treatment, and outcome.
RESULTS: Of 54 patients with PML-IRIS, 36 developed PML and IRIS simultaneously (PML-s-IRIS) and 18 had worsening of preexisting PML (PML-d-IRIS) after the initiation of combined antiretroviral therapy. PML-IRIS developed between 1 week and 26 months after initiation of antiretroviral therapy. PML-d-IRIS patients developed IRIS earlier, had higher lesion loads on MRI of the brain, had shorter durations of survival, and had higher mortality rate compared to PML-s-IRIS patients. Twelve patients received treatment with steroids, of which five died and seven showed good neurologic recovery. Patients who survived had received steroids early after IRIS diagnosis for longer durations and had contrast enhancement on IRIS neuroimaging.
CONCLUSIONS: Immune reconstitution following initiation of combined antiretroviral therapy may lead to activation of an inflammatory response to detectable or latent JC virus infection. Early and prolonged treatment with steroids may be useful in these patients but requires further investigation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19129505      PMCID: PMC2677476          DOI: 10.1212/01.wnl.0000343510.08643.74

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  39 in total

1.  The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy.

Authors:  P Cinque; C Pierotti; M G Viganò; A Bestetti; C Fausti; D Bertelli; A Lazzarin
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

2.  Inflammatory reactions in progressive multifocal leukoencephalopathy after highly active antiretroviral therapy.

Authors:  P Miralles; J Berenguer; C Lacruz; J Cosín; J C López; B Padilla; L Muñoz; D García-de-Viedma
Journal:  AIDS       Date:  2001-09-28       Impact factor: 4.177

3.  Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial?

Authors:  Renaud A Du Pasquier; Igor J Koralnik
Journal:  J Neurovirol       Date:  2003       Impact factor: 2.643

Review 4.  The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature.

Authors:  Paola Cinque; Simona Bossolasco; Anna Maria Brambilla; Antonio Boschini; Cristina Mussini; Chiara Pierotti; Adriana Campi; Salvatore Casari; Davide Bertelli; Maurizio Mena; Adriano Lazzarin
Journal:  J Neurovirol       Date:  2003       Impact factor: 2.643

5.  Placebo-controlled trial of prednisone in advanced HIV-1 infection.

Authors:  G A McComsey; C C Whalen; S D Mawhorter; R Asaad; H Valdez; A H Patki; J Klaumunzner; K V Gopalakrishna; L H Calabrese; M M Lederman
Journal:  AIDS       Date:  2001-02-16       Impact factor: 4.177

6.  Progressive multifocal leucoencephalopathy with unusual inflammatory response during antiretroviral treatment.

Authors:  C Hoffmann; H-A Horst; H Albrecht; W Schlote
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-08       Impact factor: 10.154

7.  Fatal immune restoration disease in human immunodeficiency virus type 1-infected patients with progressive multifocal leukoencephalopathy: impact of antiretroviral therapy-associated immune reconstitution.

Authors:  Amar Safdar; Ronald J Rubocki; Joseph A Horvath; Kailash K Narayan; Robert L Waldron
Journal:  Clin Infect Dis       Date:  2002-10-28       Impact factor: 9.079

8.  The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy.

Authors:  A De Luca; M L Giancola; A Ammassari; S Grisetti; M G Paglia; M Gentile; A Cingolani; R Murri; G Liuzzi; A D Monforte; A Antinori
Journal:  J Infect Dis       Date:  2000-08-31       Impact factor: 5.226

9.  Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases.

Authors:  Patricia Price; Grant Morahan; Dexing Huang; Emma Stone; Karey Y M Cheong; Alison Castley; Marina Rodgers; Meredith Q McIntyre; Lawrence J Abraham; Martyn A French
Journal:  AIDS       Date:  2002-10-18       Impact factor: 4.177

10.  Cidofovir treatment of progressive multifocal leukoencephalopathy in a patient receiving highly active antiretroviral therapy.

Authors:  R R Razonable; A J Aksamit; A J Wright; J W Wilson
Journal:  Mayo Clin Proc       Date:  2001-11       Impact factor: 7.616

View more
  107 in total

Review 1.  Management of the immune reconstitution inflammatory syndrome.

Authors:  Graeme Meintjes; James Scriven; Suzaan Marais
Journal:  Curr HIV/AIDS Rep       Date:  2012-09       Impact factor: 5.071

2.  Use of diffusion-weighted imaging to evaluate the initial response of progressive multifocal leukoencephalopathy to highly active antiretroviral therapy: early experience.

Authors:  C Buckle; M Castillo
Journal:  AJNR Am J Neuroradiol       Date:  2010-04-01       Impact factor: 3.825

3.  Proton MR spectroscopy of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome.

Authors:  V Cuvinciuc; G Martin-Blondel; B Marchou; F Bonneville
Journal:  AJNR Am J Neuroradiol       Date:  2010-06-10       Impact factor: 3.825

Review 4.  Progressive multifocal leukoencephalopathy and newer biological agents.

Authors:  Joseph R Berger
Journal:  Drug Saf       Date:  2010-11-01       Impact factor: 5.606

Review 5.  Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.

Authors:  Chen S Tan; Igor J Koralnik
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

Review 6.  Update on opportunistic infections in the era of effective antiretroviral therapy.

Authors:  Brian C Zanoni; Rajesh T Gandhi
Journal:  Infect Dis Clin North Am       Date:  2014-09       Impact factor: 5.982

7.  Neurological complications of HIV infection in pre-HAART and HAART era: a retrospective study.

Authors:  Angela Matinella; M Lanzafame; M A Bonometti; A Gajofatto; E Concia; S Vento; S Monaco; S Ferrari
Journal:  J Neurol       Date:  2015-04-01       Impact factor: 4.849

Review 8.  Neurologic complications of HIV-1 infection and its treatment in the era of antiretroviral therapy.

Authors:  Sarah M Kranick; Avindra Nath
Journal:  Continuum (Minneap Minn)       Date:  2012-12

Review 9.  Progressive multifocal leukoencephalopathy in HIV-1 infection.

Authors:  Paola Cinque; Igor J Koralnik; Simonetta Gerevini; Jose M Miro; Richard W Price
Journal:  Lancet Infect Dis       Date:  2009-10       Impact factor: 25.071

Review 10.  Drug induced increases in CNS dopamine alter monocyte, macrophage and T cell functions: implications for HAND.

Authors:  Peter J Gaskill; Tina M Calderon; Jacqueline S Coley; Joan W Berman
Journal:  J Neuroimmune Pharmacol       Date:  2013-03-01       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.